EX-25.1 20 b78349s4exv25w1.htm EX-25.1 STATEMENT OF ELIGIBILITY exv25w1
Exhibit 25.1
Registration No. 333-158542
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM T-1
STATEMENT OF ELIGIBILITY
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY
OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) þ
 
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
(Exact name of trustee as specified in its charter)
     
Delaware   95-3571558
(State of incorporation   (I.R.S. employer
if not a U.S. national bank)   identification no.)
     
700 South Flower Street, Suite 500    
Los Angeles, California   90017
(Address of principal executive offices)   (Zip code)
Robert J. Sussman, Esq.
Legal Department
The Bank of New York Mellon Trust Company, National Association
One Wall Street
New York, NY 10286
(212) 635-1089
(Name, address and telephone number of agent for service)
 
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact name of obligor as specified in its charter)
(See table of additional obligors on following page)
     
Delaware   04-3565120
(State of incorporation   (I.R.S. employer
if not a U.S. national bank)   identification no.)

 


 

     
51 Sawyer Road, Suite 200   02453
Waltham, Massachusetts   (Zip code)
(Address of principal executive offices)    
 
7.875% Senior Notes Due 2016
(Title of the indenture securities)
 

- 2 -


 

TABLE OF ADDITIONAL OBLIGORS
     Some or all of the following direct and indirect wholly owned domestic subsidiaries of Inverness Medical Innovations, Inc. are expected to guarantee the debt securities issued pursuant to the Indenture. The address, including zip code, and telephone number, including area code, of each of the co-obligors is 51 Sawyer Road, Suite 200, Waltham, Massachusetts, 02453, (781) 647-3900:
         
    State or other    
    jurisdiction of    
Exact name of additional registrant   incorporation or   I.R.S. Employer
as specified in its charter   organization   Identification Number
Alere Health, LLC
  Delaware   26-2564744
Alere Healthcare of Illinois, Inc.
  Georgia   58-2068880
Alere Health Improvement Company
  Delaware   23-2776413
Alere Health Systems, Inc.
  Delaware   22-3493126
Alere Medical, Inc.
  California   94-3238845
Alere Wellology, Inc.
  Delaware   54-1776557
Alere Women’s and Children’s Health, LLC
  Delaware   58-2205984
Ameditech Inc.
  California   33-0859551
Applied Biotech, Inc.
  California   33-0447325
Binax, Inc.
  Delaware   20-2507302
Biosite Incorporated
  Delaware   33-0288606
Cholestech Corporation
  Delaware   94-3065493
First Check Diagnostics Corp.
  Delaware   20-8329751
First Check Ecom, Inc.
  Massachusetts   33-1026518
Free & Clear, Inc.
  Delaware   20-0231080
GeneCare Medical Genetics Center, Inc.
  North Carolina   56-1348485
Hemosense, Inc.
  Delaware   77-0452938
IM US Holdings, LLC
  Delaware   26-0349667
Innovacon, Inc.
  Delaware   20-1100264
Innovative Mobility, LLC
  Florida   20-0351538
Instant Technologies, Inc.
  Virginia   54-1837621
Inverness Medical, LLC
  Delaware   26-0392649
Inverness Medical — Biostar Inc.
  Delaware   91-1929582
Inverness Medical Innovations North America, Inc.
  Delaware   26-1444559
Inverness Medical International Holding Corp.
  Delaware   20-0963463
Ischemia Technologies, Inc.
  Delaware   84-1489537
IVC Industries, Inc.
  Delaware   22-1567481
Matria of New York, Inc.
  New York   58-1873062
Matritech, Inc.
  Delaware   26-1436477
Ostex International, Inc.
  Washington   91-1450247
Quality Assured Services, Inc.
  Florida   59-3437644
Redwood Toxicology Laboratory, Inc.
  California   68-0332937
RMD Networks, Inc.
  Delaware   84-1581993
RTL Holdings, Inc.
  Delaware   20-4371685
Selfcare Technology, Inc.
  Delaware   04-3383533
Tapestry Medical, Inc.
  Delaware   20-0391730
Wampole Laboratories, LLC
  Delaware   37-1485678
ZyCare, Inc.
  North Carolina   56-1398496

- 3 -


 

1.   General information. Furnish the following information as to the trustee:
  (a)   Name and address of each examining or supervising authority to which it is subject.
     
Name   Address
Comptroller of the Currency — United States Department of the Treasury
  Washington, D.C. 20219
 
   
Federal Reserve Bank
  San Francisco, California 94105
 
   
Federal Deposit Insurance Corporation
  Washington, D.C. 20429
  (b)   Whether it is authorized to exercise corporate trust powers.
 
      Yes.
2.   Affiliations with Obligor.
 
    If the obligor is an affiliate of the trustee, describe each such affiliation.
 
    None.
 
16.   List of Exhibits.
Exhibits identified in parentheses below, on file with the Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule 7a 29 under the Trust Indenture Act of 1939 (the “Act”) and 17 C.F.R. 229.10(d).
  1. A copy of the articles of association of The Bank of New York Mellon Trust Company, N.A., formerly known as The Bank of New York Trust Company, N.A. (Exhibit 1 to Form T-1 filed with Registration Statement No. 333-121948 and Exhibit 1 to Form T-1 filed with Registration Statement No. 333-152875 which is incorporated by reference).
 
  2.   A copy of certificate of authority of the trustee to commence business. (Exhibit 2 to Form T-1 filed with Registration Statement No. 333-121948) which is incorporated by reference.
 
  3.   A copy of the authorization of the trustee to exercise corporate trust powers (Exhibit 3 to Form T-1 filed with Registration Statement No. 333-152875 which is incorporated by reference).
 
  4.   A copy of the existing by laws of the trustee (Exhibit 4 to Form T-1 filed with Registration Statement No. 333-152875 which is incorporated by reference).
 
  5.   Not applicable.

- 4 -


 

  6.   The consent of the trustee required by Section 321(b) of the Act (Exhibit 6 to Form T-1 filed with Registration Statement No. 333-152875 which is incorporated by reference).
 
  7.   A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority.
 
  8.   Not applicable.
 
  9.   Not applicable.

- 5 -


 

SIGNATURE
     Pursuant to the requirements of the Act, the trustee, The Bank of New York Mellon Trust Company, N.A., a banking association organized and existing under the laws of the United States of America, has duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in The City of Boston, and State of Massachusetts, on the 12th day of February, 2010.
         
  THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
 
 
  By:   /s/ Peter M. Murphy  
    Name:   Peter M. Murphy  
    Title:   Vice President  
 

- 6 -


 

EXHIBIT 7
Consolidated Report of Condition of
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. of 700 South
Flower Street, Suite 200, Los Angeles, CA 90017
     At the close of business September 30, 2009, published in accordance with Federal regulatory authority instructions.
             
        Dollar Amounts  
        in Thousands  
ASSETS
           
 
Cash and balances due from depository institutions:
           
Noninterest-bearing balances and currency and coin
        1,585  
Interest-bearing balances
        426  
Securities:
           
Held-to-maturity securities
        16  
Available-for-sale securities
        553,806  
Federal funds sold and securities purchased under agreements to resell:
           
Federal funds sold
        83,000  
Securities purchased under agreements to resell
        0  
Loans and lease financing receivables:
           
Loans and leases held for sale
        0  
Loans and leases, net of unearned income
  0        
LESS: Allowance for loan and lease losses
  0        
Loans and leases, net of unearned income and allowance
        0  
Trading assets
        0  
Premises and fixed assets (including capitalized leases)
        10,983  
Other real estate owned
        0  
Investments in unconsolidated subsidiaries and associated companies
        1  
Direct and indirect investments in real estate ventures
        0  
Intangible assets:
           
Goodwill
        852,858  
Other intangible assets
        251,145  
Other assets
        156,398  
 
         
Total assets
      $ 1,910,218  
 
         

1


 

             
        Dollar Amounts  
        in Thousands  
LIABILITIES
           
 
           
Deposits:
           
In domestic offices
        1,712  
Noninterest-bearing
  1,712        
Interest-bearing
  0        
Not applicable
           
Federal funds purchased and securities sold under agreements to repurchase:
           
Federal funds purchased
        0  
Securities sold under agreements to repurchase
        0  
Trading liabilities
        0  
Other borrowed money:
           
(includes mortgage indebtedness and obligations under capitalized leases)
        268,691  
Not applicable
           
Not applicable
           
Subordinated notes and debentures
        0  
Other liabilities
        198,124  
Total liabilities
        468,527  
Not Applicable
           
 
           
EQUITY CAPITAL
           
 
           
Perpetual preferred stock and related surplus
        0  
Common stock
        1,000  
Surplus (exclude all surplus related to preferred stock)
        1,121,520  
Not Applicable
           
Retained earnings
        316,907  
Accumulated other comprehensive income
        2,264  
Other equity capital components
        0  
Not Available
           
Total bank equity capital
        1,441,691  
Noncontrolling (minority) interests in consolidated subsidiaries
        0  
Total equity capital
        1,441,691  
 
         
Total liabilities and equity capital
        1,910,218  
 
         
     I, Karen Bayz, Managing Director of the above-named bank do hereby declare that the Reports of Condition and Income (including the supporting schedules) for this report date have been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and are true to the best of my knowledge and belief.
     Karen Bayz    )                Managing Director
     We, the undersigned directors (trustees), attest to the correctness of the Report of Condition (including the supporting schedules) for this report date and declare that it has been examined by us and to the best of our knowledge and belief has been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and is true and correct.
             
Troy Kilpatrick, MD
    )      
Frank P. Sulzberger, MD
    )     Directors (Trustees)
William D. Lindelof, MD
    )      

2